We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current NBIX market cap is 14.07B. The company's latest EPS is USD 2.5094 and P/E is 55.65.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 420.4M | 452.7M | 498.8M | 515.2M | 515.3M |
| Operating Income | -114.2M | 73.6M | 141.2M | 150.3M | 99.3M |
| Net Income | -76.6M | 95.5M | 83.1M | 147.7M | 43.4M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 788.09M | 1.05B | 1.13B | 1.49B | 1.89B |
| Operating Income | 72.28M | 163M | 102.5M | 249M | 250.9M |
| Net Income | 37.01M | 407.3M | 89.6M | 154.5M | 249.7M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 2.36B | 2.61B | 2.85B | 3.25B | 3.47B |
| Total Liabilities | 675.3M | 760.1M | 846.1M | 1.02B | 1.09B |
| Total Equity | 1.68B | 1.85B | 2B | 2.23B | 2.39B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.31B | 1.73B | 2.07B | 2.37B | 3.25B |
| Total Liabilities | 669.12M | 608.5M | 698.5M | 660.9M | 1.02B |
| Total Equity | 636.92M | 1.13B | 1.37B | 1.71B | 2.23B |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -125.2M | 54.4M | 266.4M | 389.9M | 130.3M |
| Investing | -42.1M | -168M | -265.3M | -467.1M | -55M |
| Financing | 8.2M | 11.1M | 29.9M | 65.3M | 69.9M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 152.05M | 228.5M | 256.5M | 339.4M | 389.9M |
| Investing | -211.07M | 4.1M | -130.2M | -177.1M | -467.1M |
| Financing | 27.31M | -157.8M | 27.4M | -234.3M | 65.3M |
| Market Cap | 14.07B |
| Price to Earnings Ratio | 55.65 |
| Price to Sales Ratio | 7.36 |
| Price to Cash Ratio | 55.34 |
| Price to Book Ratio | 6.23 |
| Dividend Yield | - |
| Shares Outstanding | 99.51M |
| Average Volume (1 week) | 705.25k |
| Average Volume (1 Month) | 735.97k |
| 52 Week Change | 50.97% |
| 52 Week High | 148.3699 |
| 52 Week Low | 89.04 |
| Spread (Intraday) | 0.16 (0.11%) |
| Company Name | Neurocrine Biosciences Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.neurocrine.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
